Search Results
Your search for The A matches 34826 pages
Showing 1 - 50FDA Approves Pimicotinib for Symptomatic TGCT
On November 10, the U.S. Food and Drug Administration (FDA) approved pimicotinib (Pimjetmi), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgical resection may cause worsening functional limitation or severe morbidity. MANEUVER Trial Efficacy was...
JCO Announces New Editor-in-Chief
ASCO is pleased to name Thomas E. Stinchcombe, MD, FASCO as the new Editor-in-Chief of the Journal of Clinical Oncology (JCO). A long-standing leader in academic publishing and Fellow of ASCO, Dr. Stinchcombe brings years of dedication to JCO as a top peer reviewer and associate editor, alongside...
ASCO and ESMO Issue Joint Consensus Calling for Streamlined Clinical Research Under Updated International Standards
ASCO and the European Society for Medical Oncology (ESMO) have released a joint consensus statement highlighting strategies to reduce administrative burden and streamline cancer clinical trials. The statement focuses on leveraging newly updated guidelines from the International Council for...
Beyond Chemotherapy: Overall Survival Nearly Doubled With Investigational Immunotherapy in Advanced Squamous NSCLC
Updated findings from Stage 1 of the multicenter, international, two-stage phase III PRESERVE-003 trial showed that, among patients with metastatic squamous non–small cell lung cancer (NSCLC) whose disease had progressed following anti–PD-(L)1 therapy, treatment with the investigational anti–CTLA-4 ...
Preventing Africa’s Coming Cancer Crisis: The Harm Reduction Imperative
Africa is heading toward a cancer catastrophe, and the oncology community must not look away. Noncommunicable diseases already account for 37% of all deaths in the WHO African Region, up from 24% in 2000, and nearly two-thirds of these deaths occur prematurely, before 70.1,2These are not distant...
First-Line T-DXd: A Change of DESTINY for HER2-Mutant NSCLC?
In patients with advanced HER2-mutant non–small cell lung cancer (NSCLC), first-line monotherapy with the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) significantly prolonged progression-free survival compared with standard-of-care chemoimmunotherapy. This was...
Nobel Prize in Physiology or Medicine 2026 Awarded for Optogenetics
The Nobel Assembly at Karolinska Institutet has awarded the 2026 Nobel Prize in Physiology or Medicine jointly to Karl Deisseroth, MD, PhD, of The Howard Hughes Medical Institute and Stanford University, California; Peter Hegemann, PhD, of Humboldt University of Berlin, Germany; and Georg Nagel,...
U.S. Food and Drug Administration Expanded Indications and Approvals in Bladder and Colorectal Cancers
Several approvals by the U.S. Food and Drug Administration (FDA) over the past month included therapeutics for patients with BCG-unresponsive non–muscle-invasive bladder cancer and locally advanced rectal cancer. Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBC On October 14, 2026, the FDA...
AI Diagnostics and What Clinicians Can Verify in Oncology
When artificial intelligence (AI) is applied to medical images, it can improve physicians’ diagnostic capabilities as well as identify features that humans are unable to see. From identifying biomarkers to guiding treatment decisions, AI in medical imaging has already demonstrated numerous...
Of Note in the Oncology Community
Carl June, MD, of the University of Pennsylvania and Michel Sadelain, MD, PhD, of Columbia University, received the 2026 International Steven Hoogendijk Award for Medical Engineering in Rotterdam, the Netherlands, on October 2. The researchers were recognized for their pioneering contributions to...
Funda Meric-Bernstam, MD, on Platinum-Resistant Ovarian Cancer: Torvutatug Samrotecan
Funda Meric-Bernstam, MD, of The University of Texas MD Anderson Cancer Center, reviews updated results from the FONTANA trial, a phase I/IIa, first-in-human, open-label study, which is evaluating the safety and efficacy of torvutatug samrotecan, a folate receptor α–targeted antibody-drug...
Two ‘Forever Chemicals’ Associated With Higher Risk of ER-Negative Breast Cancer
Higher blood concentrations of two common per- and polyfluoroalkyl substances (PFAS) were associated with an increased incidence of estrogen receptor (ER)-negative breast cancer among women participating in the Sister Study, according to research published by Chang et al in the Journal of Clinical ...
Methylphenidate May Reduce Cancer-Related Fatigue in Patients With Hematologic Malignancies
Treatment with the norepinephrine-dopamine reuptake inhibitor methylphenidate significantly reduced cancer-related fatigue in patients with hematologic malignancies compared with placebo, according to findings from the randomized, double-blind, crossover MICRO trial reported by Frederiksen et al in ...
ROSELLA Subgroup Analysis Supports Relacorilant Use in Patients Previously Treated With Taxanes
Can patients with platinum-resistant ovarian cancer treated with taxane therapy benefit from receiving relacorilant after a taxane? A new subgroup analysis from the phase III ROSELLA trial1 suggests the answer may be yes. The analysis, presented at the 2026 ASCO Annual Meeting, focused on prior...
Extended Follow-up of Nivolumab/Ipilimumab for Localized dMMR/MSI-H Gastric/GEJ Cancer
Neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab was associated with sustained long-term survival in patients with localized mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) gastric or gastroesophageal junction (GEJ) adenocarcinoma, based on updated...
Ponatinib/Blinatumomab Improves Event-Free Survival in Ph-Positive ALL
A chemotherapy-free front-line regimen of ponatinib plus blinatumomab significantly improved event-free survival compared with imatinib plus chemotherapy in adults with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). Chiaretti et al reported results from...
American Lung Association and Prevent Cancer Foundation Host Virtual QIW Workshop: Advancing Routine Clinical Use of Health Information From Chest CT Screening for Public Health
The Quantitative Imaging Workshop (QIW) brings together leading experts from around the world for the advancement of quantitative low-dose computed tomography (CT) imaging biomarkers for detection and management of early chest diseases including lung cancer, chronic obstructive pulmonary disease,...
Izalontamab Brengitecan Improves Progression-Free Survival in EGFR-Mutated Advanced Nonsquamous NSCLC
In the phase III PANKU-Lung01 trial, the bispecific antibody–drug conjugate izalontamab brengitecan significantly improved progression-free survival compared with platinum-based chemotherapy in patients with EGFR-mutated advanced nonsquamous non–small cell lung cancer (NSCLC) whose disease had...
FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC
On November 5, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based...
Pediatric Brain Tumors: Prognostic AI Model Guides Precision Therapy Choices
An artificial intelligence (AI) model built based on DNA methylation profiling provided a look at outcomes for children with medulloblastoma and ependymoma, according to study findings published in Nature Genetics. The model may be used to guide personalized treatment decisions, including treatment ...
Anthony B. El-Khoueiry, MD, Named Director of the USC Norris Comprehensive Cancer Center
Anthony B. El-Khoueiry, MD, has been appointed Director of the University of Southern California (USC) Norris Comprehensive Cancer Center, effective November 1. Prior to the appointment, Dr. El-Khoueiry served as Associate Director for Clinical Research, Medical Director of the Clinical...
Keeping PACE With Surgery: SBRT for Localized Prostate Cancer
An updated efficacy analysis of the international phase III PACE-A trial showed high rates of freedom from biochemical or clinical failure (BCF) with both stereotactic body radiation therapy (SBRT) and radical prostatectomy in patients with localized prostate cancer, with no statistically...
HERON-Lung01: HER3-Directed ADC Prolongs Progression-Free Survival in EGFR-Mutated Advanced NSCLC
In the phase III HERON-Lung01 trial, ruzaltatug rezetecan significantly prolonged progression-free survival compared with chemotherapy and showed a manageable safety profile in patients with EGFR tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutated advanced non–small cell lung cancer (NSCLC),...
Basser Center for BRCA Awards 2026 Global Prize
The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, the world’s first comprehensive center aimed at advancing research, treatment, and prevention of BRCA-related cancers, has named Judy E. Garber, MD, MPH, of Dana-Farber Cancer Institute, as the recipient of...
Trine Jakobi Nøttrup, MD, PhD, on BRCA Wild-Type Recurrent Ovarian Cancer: Novel Triplet Maintenance Regimen
Trine Jakobi Nøttrup, MD, PhD, of Rigshospitalet, describes findings from the DOVACC trial, which evaluated the combination of olaparib, durvalumab, and UV1—a therapeutic cancer vaccine directed against human telomerase reverse transcriptase—as maintenance therapy in patients with BRCA wild-type...
Bispecific ADC May Offer New Treatment Option for HR-Positive, HER2-Negative Breast Cancer
The EGFR and HER3 bispecific antibody–drug conjugate izalontamab brengitecan significantly improved progression-free survival vs chemotherapy in heavily pretreated Chinese patients with hormone receptor–positive, HER2-negative breast cancer, according to results from the multicenter phase III...
IOF Issues Position Statement on Bone Fragility Management for Patients With MGUS
The International Osteoporosis Foundation (IOF) Committee of Scientific Advisors (CSA) Bone and Cancer Working Group has released a position statement on bone fragility in patients with monoclonal gammopathy of undetermined significance (MGUS). The new statement provides guidance on how to...
First-Line Pembrolizumab Improves Progression-Free Survival in dMMR Advanced Endometrial Cancer
First-line pembrolizumab monotherapy significantly improved progression-free survival compared with carboplatin plus paclitaxel in patients with mismatch repair–deficient (dMMR) advanced or recurrent endometrial cancer, according to an interim analysis of the phase III...
Wake Forest University School of Medicine Names Inaugural Chair of the Department of Cancer Medicine
Antoinette R. Tan, MD, MHSc, FACP, FASCO, has been appointed inaugural Chair of the newly formed Department of Cancer Medicine for the Charlotte, North Carolina campus of Wake Forest University School of Medicine. A clinician-scientist, Dr. Tan is a nationally recognized breast medical oncologist...
Perlmutter Cancer Center Names Director of Early-Phase Drug Development and Rare Cancer Programs
NYU Langone Health announced the appointment of Vivek Subbiah, MD, as Director of the Early Phase Drug Development Program and the Rare Cancer Program at NYU Langone’s Perlmutter Cancer Center, effective November 1. He will also serve as Professor in the Department of Medicine’s Division of...
Domenica Lorusso, MD, PhD, on Sacituzumab Tirumotecan in Previously Treated Advanced or Recurrent Endometrial Cancer
Domenica Lorusso, MD, PhD, of Humanitas University, summarizes findings from the phase III TroFuse-005/ENGOT-en23/GOG-3095 study, which showed sacituzumab tirumotecan, a TROP2-directed antibody-drug conjugate, provided statistically significant and clinically meaningful improvements in...
Kohei Shitara, MD, on G-HOPE 001: Arcotatug Tavatecan in GI/GEJ Cancer
Kohei Shitara, MD, of the National Cancer Center Hospital East in Kashiwa, Japan, presents findings from the prespecified first interim analysis of the phase III G-HOPE 001 trial, which showed that arcotatug tavatecan, a CLDN18.2-targeted antibody-drug conjugate, demonstrated a statistically...
Upcoming ASCO AI in Oncology Webinar Turns Chatbot Printouts Into Better Patient Conversations
When a patient brings in a list of questions or suggestions from their favorite chatbot about their cancer diagnosis or treatment, how should a physician respond? Should they immediately explain the issues with artificial intelligence (AI) knowledge of clinical subjects? Should they try to educate...
HER2-Positive Targeted Therapy Cardiovascular Risk: ACC Upcoming Journal Club
The American College of Cardiology's (ACC)'s specialty journal JACC: CardioOncology invites fellows and trainees to participate in a journal club to explore influential cardiovascular and cardio-oncology studies shaping clinical practice. The next event takes place November 18, 2026, at 11:00 AM...
A Fraction of the Fractions: SBRT Before Pancreatic Cancer Surgery
Patients preparing to undergo surgery for pancreatic adenocarcinoma who received stereotactic body radiation therapy (SBRT) appeared to have comparable pathologic and surgical outcomes while reporting better quality of life during treatment than those who received conventionally fractionated...
Hypofractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation Demonstrates Noninferior Locoregional Control
A hypofractionated radiotherapy regimen was noninferior to conventional radiotherapy for locoregional control among patients with high-risk breast cancer undergoing postmastectomy radiotherapy with internal mammary node irradiation, according to findings from the phase III HypoMast-IMNI trial...
Neoadjuvant Niraparib Shows Activity in HRD-Positive Advanced Ovarian Cancer
Neoadjuvant niraparib monotherapy produced tumor responses and enabled complete resection in selected patients with homologous recombination deficiency (HRD)-positive advanced ovarian cancer who were considered unlikely to achieve complete primary debulking surgery. Dan Liu, MD, and colleagues...
Researchers Explore Potential Strategy for Overcoming Resistance to RAS Inhibitors
In a preclinical study published recently in Cancer Research, investigators identified a strategy that may help guide future clinical strategies for overcoming treatment resistance associated with KRAS-targeted cancer therapies. This preclinical study was led by Roswell Park Comprehensive Cancer...
Yelena Y. Janjigian, MD, FASCO, on CLARITY-Gastric 01: Sonesitatug Vedotin in CLDN18.2-Positive Gastroesophageal Cancer
Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center—a co-chair of a Presidential Symposium at the ESMO Congress 2026—reviews results from the phase III trial that looked at the CLDN18.2-targeting antibody-drug conjugate sonesitatug vedotin vs investigator’s choice of therapy...
Elizabeth Smyth, MD, on Esophageal/GEJ Cancer: Pembrolizumab or Placebo Plus Concurrent Definitive Chemoradiotherapy
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses data from the phase III KEYNOTE-975 study, which examined definitive chemoradiotherapy with or without pembrolizumab in patients with previously untreated locally advanced unresectable esophageal and...
Elizabeth Smyth, MD, on Gastric/GEJ Cancer: Novel CLDN18.2-Targeting ADC
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, reviews results from the phase III G-HOPE-001 trial, which evaluated the CLDN18.2-targeted antibody-drug conjugate arcotatug tavatecan in previously treated patients with gastric or gastroesophageal junction (GEJ)...
Optimizing Treatment for Relapsed/Refractory Follicular Lymphoma
For patients with relapsed or refractory follicular lymphoma, the timing of progression is one of the factors Peter A. Riedell, MD, considers when choosing the next treatment. A long first remission may support another course of chemoimmunotherapy, but progression within 24 months of starting...
Current Public Knowledge Rates on Alcohol and Cancer Risks
According to a nationally representative survey conducted in October by the Annenberg Public Policy Center of the University of Pennsylvania, the number of Americans aware of the connection between alcohol consumption and an increased risk of cancer has increased to 58%. The policy center has been ...
Study Reveals Distinct Cellular and Genetic Differences in Early-Onset Colorectal Cancer
Mass General Brigham researchers from the Gene Lay Institute of Immunology and Inflammation, along with researchers at Dana-Farber Cancer Institute and the Broad Institute, have identified biological differences in colorectal tumors that may help explain why the disease can behave more aggressively ...
OptiTROP-Lung06: A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?
In patients with advanced PD-L1–negative nonsquamous non–small cell lung cancer (NSCLC) without targetable genomic alterations, first-line treatment with the Trop-2–directed antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab demonstrated a significant progression-free survival...
ASTRO Updates Guideline on Shorter-Course Radiation Therapy for Localized Prostate Cancer
An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of hypofractionated radiation therapy for patients with localized prostate cancer. The guideline replaces ASTRO’s 2018 recommendations and reflects a...
Selpercatinib, Sacituzumab Govitecan Show Activity in Thyroid Cancer Subtypes
Researchers from Vall d’Hebron University Hospital presented advances in targeted therapies for patients with thyroid cancer during the ESMO Congress 2026. Updated results of the phase III LIBRETTO-531 trial showed durable benefits with selpercatinib compared with existing targeted therapies for...
Financial Navigation Program May Help Reduce Cancer-Related Financial Hardship
A financial navigation intervention was associated with significant reductions in financial toxicity among patients with cancer across rural and nonrural oncology practices, according to findings from the Lessening the Impact of Financial Toxicity (LIFT) trial reported by Wheeler et al in the...
Disitamab Vedotin Plus Tislelizumab Shows Activity in Very High–Risk Non–Muscle-Invasive Bladder Cancer
Treatment with the anti-ERBB2 antibody-drug conjugate disitamab vedotin plus the anti–PD-1 immune checkpoint inhibitor tislelizumab-jsgr showed evidence of antitumor activity in patients with transurethrally unresectable, ERBB2-positive, very high–risk non–muscle invasive bladder cancer, according...
How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation
In 2024, ASCO updated its guideline for the integration of palliative care in oncology, which recommends that clinicians refer patients with advanced solid tumors and hematologic malignancies to specialized interdisciplinary palliative care teams beginning early in the course of a patient’s disease ...
